Palatin Technologies is expected to report a consensus revenue of $0.83 million and an EPS loss of $1.20 for the quarter ending June 30, 2026, while the stock currently trades at $12.84 against an average analyst target of $53.50.
Investors are primarily focused on clinical updates regarding Palatin's melanocortin-based obesity pipeline, specifically the progress toward an Investigational New Drug (IND) submission for its once-weekly injectable peptide.
The company recently shifted its strategy to prioritize next-generation oral MC4R agonists, extending the oral program's timeline to early 2027 while keeping the injectable candidate on track for a late 2026 clinical initiation. Recent financial stability has been bolstered by an $18.2 million public offering and milestones from partnerships in retinal and dry eye diseases.